348 related articles for article (PubMed ID: 20213764)
21. Irisin Enhances Doxorubicin-Induced Cell Apoptosis in Pancreatic Cancer by Inhibiting the PI3K/AKT/NF-κB Pathway.
Liu J; Huang Y; Liu Y; Chen Y
Med Sci Monit; 2019 Aug; 25():6085-6096. PubMed ID: 31412018
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer.
Banerjee S; Kaseb AO; Wang Z; Kong D; Mohammad M; Padhye S; Sarkar FH; Mohammad RM
Cancer Res; 2009 Jul; 69(13):5575-83. PubMed ID: 19549912
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
[TBL] [Abstract][Full Text] [Related]
24. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells.
Holcomb BK; Yip-Schneider MT; Waters JA; Beane JD; Crooks PA; Schmidt CM
J Gastrointest Surg; 2012 Jul; 16(7):1333-40. PubMed ID: 22618517
[TBL] [Abstract][Full Text] [Related]
25. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.
Morgan MA; Parsels LA; Kollar LE; Normolle DP; Maybaum J; Lawrence TS
Clin Cancer Res; 2008 Aug; 14(16):5142-9. PubMed ID: 18698032
[TBL] [Abstract][Full Text] [Related]
26. {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.
Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Yadav VR; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
Cancer Res; 2010 Nov; 70(21):8695-705. PubMed ID: 20864511
[TBL] [Abstract][Full Text] [Related]
27. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.
Harikumar KB; Kunnumakkara AB; Sethi G; Diagaradjane P; Anand P; Pandey MK; Gelovani J; Krishnan S; Guha S; Aggarwal BB
Int J Cancer; 2010 Jul; 127(2):257-68. PubMed ID: 19908231
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts.
Mohammad RM; Banerjee S; Li Y; Aboukameel A; Kucuk O; Sarkar FH
Cancer; 2006 Mar; 106(6):1260-8. PubMed ID: 16475211
[TBL] [Abstract][Full Text] [Related]
29. Vitamin E δ-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-κB activation in pancreatic cancer.
Husain K; Francois RA; Yamauchi T; Perez M; Sebti SM; Malafa MP
Mol Cancer Ther; 2011 Dec; 10(12):2363-72. PubMed ID: 21971120
[TBL] [Abstract][Full Text] [Related]
30. Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells.
Torres C; Linares A; Alejandre MJ; Palomino-Morales RJ; Delgado JR; Perales S
Pancreas; 2016 Feb; 45(2):269-80. PubMed ID: 26495790
[TBL] [Abstract][Full Text] [Related]
31. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
Ng SS; Tsao MS; Nicklee T; Hedley DW
Mol Cancer Ther; 2002 Aug; 1(10):777-83. PubMed ID: 12492110
[TBL] [Abstract][Full Text] [Related]
32. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
33. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
[TBL] [Abstract][Full Text] [Related]
34. Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer.
Gong J; Xie J; Bedolla R; Rivas P; Chakravarthy D; Freeman JW; Reddick R; Kopetz S; Peterson A; Wang H; Fischer SM; Kumar AP
Clin Cancer Res; 2014 Mar; 20(5):1259-73. PubMed ID: 24520096
[TBL] [Abstract][Full Text] [Related]
35. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.
Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
Int J Cancer; 2012 Aug; 131(3):E292-303. PubMed ID: 21935918
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
Higgins B; Kolinsky K; Smith M; Beck G; Rashed M; Adames V; Linn M; Wheeldon E; Gand L; Birnboeck H; Hoffmann G
Anticancer Drugs; 2004 Jun; 15(5):503-12. PubMed ID: 15166626
[TBL] [Abstract][Full Text] [Related]
37. Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo.
Wang SJ; Gao Y; Chen H; Kong R; Jiang HC; Pan SH; Xue DB; Bai XW; Sun B
Cancer Lett; 2010 Jul; 293(1):99-108. PubMed ID: 20137856
[TBL] [Abstract][Full Text] [Related]
38. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
Shin DM; Zhang H; Saba NF; Chen AY; Nannapaneni S; Amin AR; Müller S; Lewis M; Sica G; Kono S; Brandes JC; Grist WJ; Moreno-Williams R; Beitler JJ; Thomas SM; Chen Z; Shin HJ; Grandis JR; Khuri FR; Chen ZG
Clin Cancer Res; 2013 Mar; 19(5):1244-56. PubMed ID: 23422093
[TBL] [Abstract][Full Text] [Related]
39. Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells.
Yu Y; Wang J; Xia N; Li B; Jiang X
Oncol Rep; 2015 Apr; 33(4):1683-90. PubMed ID: 25633045
[TBL] [Abstract][Full Text] [Related]
40. 3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer.
Banerjee S; Wang Z; Kong D; Sarkar FH
Cancer Res; 2009 Jul; 69(13):5592-600. PubMed ID: 19531648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
